The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its recommendations for pneumococcal vaccine in high-risk adults.
GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.